Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.
If you have Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection that lowers blood sugar and helps you lose significant weight, often outperforming other common diabetes medications and insulin. While it can cause temporary stomach issues like nausea, these are usually mild and manageable, and the long-term benefits for your heart, kidneys, and overall metabolic health are substantial.
Tirzepatide demonstrated outstanding efficacy in both glycemic management and weight loss, making it an effective tool for integrated treatment of T2DM and obesity... In SURPASS-2, tirzepatide demonstrated superiority over semaglutide in all studied doses... In SURPASS-3 and SURPASS-4, tirzepatide showed more pronounced reduction in HbA1c and weight loss compared to insulin degludec and glargine.
Why this rating
Based on multiple large-scale, randomized, controlled trials (SURPASS program) with consistent positive results.
Source
New horizons in the management of metabolic diseases: Focus on the efficacy and safety of tirzepatide
T. Yu. Demidova et al. · FOCUS Endocrinology · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →